Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Offers To Help ‘Innovation Passport’ Holders Tackle Market Access Challenges

Executive Summary

The option of receiving early, joined-up advice from HTA bodies in England, Scotland and Wales is among several tools that companies can use if their product is admitted to the UK’s Innovative Licensing and Access Pathway.

You may also be interested in...



New UK Pathway Use Has ‘Far Exceeded Expectations’

Oncology products accounted for the largest proportion of requests for a UK “innovation passport” last year, with a wide variety of drug sponsors deciding to use the new ILAP, according to the UK regulator, the MHRA.

UK Regulator Issues 41 ‘Innovation Passports’ In First Year Of New Pathway

The UK’s ILAP, a post-Brexit scheme introduced in 2021 to accelerate the development of, and access to, new innovative medicines, proved popular in its first year of operation. A total of 71 applications were received last year from companies wanting to take advantage of the regulatory advice, tools and flexibilities on offer.

The Story So Far: The UK’s New Licensing And Access Pathway

As the UK’s new pathway for innovative drugs approaches the end of its first year of operation, representatives of the national regulatory agency and England’s HTA body assess progress so far, including the greater role assigned to patients in the system.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145776

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel